CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In-vitro treatment of the HD PBMNCs and CD34+ cells with acitretin in combination with imatinib did not significantly affect the viability of these cells as measured by apoptosis assay, suggesting that this effect is unique to CML cells (Supplementary Figures S9A, B).